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INTRODUCTION
Coronary  Artery  Disease  is  defined  as  “an  impairment  of  heart  function  due  to 
inadequate blood flow to the heart compared to its needs, caused by obstructive  changes in the 
coronary circulation to the heart”.
It has been declared by WHO as a Modern epidemic.
It was the brilliant work of Herrick in 1912 who performed autopsy on AMI patients, 
that put forward the new concept of thrombotic occlusion of coronary artery as the cause of 
downstream necrosis of heart muscle.
The  definitive  proof  for  the  above  said  concept  came  from  angiographic  studies 
performed during the early hours of acute coronary event.
This prompted scientists to systematically test the thrombolytic strategies to treat AMI, 
opening a new era of thrombolytic therapy in AMI.
Scientists  have  developed  many  effective  thrombolytic  drugs  like  streptokinase, 
tenecteplase,  reteplase,  urokinase, APSAC (Anisoylated plasminogen streptokinase activator 
complex) etc.
Evidence  for  the  use  of  thrombolytic  therapy  came from large  multicentric  studies. 
GISSI and ISIS – 2 confirmed decrease in mortality with the early use of streptokinase. ISA 
(I.V.SK in acute MI study group) also stands as a proof of efficiency of thrombolytic drugs to 
decrease mortality.
Success rate of thrombolysis  and thus the overall  reduction of  mortality  is  different 
among different agents  used.  The GUSTO-1 trial  showed a 30 days mortality  of 6.3% for 
accelerated t-pA versus 7.4% for SK with I.V. heparin.
But because of the prohibitive cost of tpA, SK became the sheet anchor for thrombolytic 
therapy in GRH. Thrombolytic treatment has revolutionised the management of AMI. GUSTO 
angiographic substudy showed a success rate of 54% at 90 mins using I.V. SK and heparin.
Thrombolytic  treatment  has  been  consistently  proven  to  reduce  the  mortality  and 
morbidity. Inspite of this it has been recognized that thrombolytic treatment has failed in a 
significant population. There is a lot of room for improvement. We need to identify the factors 
that are responsible for failure of thrombolysis. 
Smoking is a proven risk factor for acute MI. There have’nt been too many studies done 
to  analyse  the  effect  of  various  factors  influencing  outcome  of  thrombolysis  among  non 
smokers.  Studies have been done predominantly  to  know the influence of  smoking on the 
outcome thrombolysis.
With this back ground, we decided to look into our own patients (non smokers) who 
receive SK for Acute MI in the ICCU of GRH.
AIM OF STUDY
1. To find out the overall success rate of thrombolysis in ICCU of GRH among non 
smokers.
2. To find out whether the following parameters influence the outcome of thrombolysis 
among non smokers. 
a. Age
b. Sex
c. Systemic Hypertension
d. Diabetes mellitus
e. Location of Myocardial infarction
f. Time interval between onset of pain and initiation of thrombolytic therapy.
REVIEW OF LITERATURE
CORONARY CIRCULATION
The coronary circulation is unique in that it is responsible for generating the arterial 
pressure that is required to perfuse the systemic circulation and yet, at the same time, has its 
own perfusion impeded during the systolic portion of the cardiac cycle. Because myocardial 
contraction is closely connected to coronary flow and oxygen delivery, the balance between the 
oxygen supply and demand is a critical determinant of the normal beat to beat function of the 
heart. When this relationship is acutely disrupted by diseases affecting the coronary blood flow, 
the resulting imbalance can immediately precipitate a vicious cycle, whereby ischemia induced 
contractile  dysfunction  precipitates  hypotension  and  further  myocardial  ischemia.  Thus  a 
knowledge  of  the  regulation  of  coronary  blood  flow,  determinants  of  myocardial  oxygen 
consumption, and the relationship between ischemia and contraction is essential. 
In contrast to most other vascular beds, myocardial oxygen extraction is near maximal at 
rest, averaging approximately 75% of arterial oxygen content2.
BLOOD SUPPLY TO THE HEART
The epicardial coronary artery system61 consists of the left and right coronary arteries, 
which normally arise from ostia, located in the left and right sinuses of valsalva, respectively. 
In about 50% of humans a “third coronary artery” (conus artery) arises from a separate ostium 
in the right sinus.
The left main (LM)  coronary artery  bifurcates into the left anterior descending (LAD) 
and left circumflex (LCX) branches62. The dominant right coronary artery (RCA) gives rise to 
the posterior descending artery (PDA).
BRANCHES OF THE MAJOR EPICARDIAL ARTERIES
The branches of the LAD artery, in their usual order of origin, are the first diagonal, the 
first  septal perforator,  the right ventricular (not always seen in normal hearts),  other septal 
perforators and other diagonal branches.
The branches of the LCX are variable but may include the sinus node artery (40 – 50%), 
the left  atrial circumflex branch, one or more posterolateral marginals and the PDA  (10 – 
15%).
The branches of the RCA include the conus artery, the artery to the sinus node (50 – 
60%),  several  anterior  right  ventricular  branches,  right  atrial  branches,  the  acute  marginal 
branch,  the  artery  to  the  AV node  and  proximal  bundle  branches,  the  PDA and  terminal 
branches to the left  ventricle and left  atrium. In 40 – 50% of hearts  the sinus node artery 
originates from the proximal LCX.
CORONARY ARTERY DISTRIBUTION AND MYOCARDIAL SUPPLY
 In the current era of reperfusion therapy for evolving acute myocardial infarction, it has 
become popular to refer to the “infarct artery” of the “ventricular myocardium” at risk.
Generally, the basal half of the ventricular septum and the anterior left ventricular free 
wall  is  perfused  by  the  LAD coronary  artery.  A  dominant  right  coronary  artery  perfuses 
anterior,  lateral  and  posterior  right  ventricular  myocardium.  The  posterior  coronary  artery 
(most commonly arising from the RCA) supplies blood to the apical half of the ventricular 
septum and posterior left ventricular free wall. The LCX coronary artery usually perfuses the 
lateral  wall  of  the  left  ventricle  (defined as  the  portion of  ventricular  myocardium located 
between anterolateral and posteromedial papillary muscles). Unappreciated areas of coronary 
perfusion include the basal ventricular septum and left ventricular apex. The basal most portion 
of the ventricular septum is usually perfused by branches of the PDA. The apical third of the 
posterior left ventricle may be predominantly perfused by the LAD artery.
At present it is believed that the LAD artery and its branches nourish the apical wall of 
left ventricle, most of the right and left bundle branches, and the antero lateral papillary muscle 
of the left ventricle. When the PDA is provided by the circumflex artery, the entire septum is 
vascularized  by  the  left  coronary  system63.  The  LAD  artery  can  also  provide  collateral 
circulation to the anterior right ventricle.
CORONARY AUTOREGULATION
Regional coronary blood flow remains constant as coronary artery pressure is reduced 
below  aortic  pressure  over  a  wide  range  when  the  determinants  of  myocardial  oxygen 
consumption are kept constant3.  This phenomenon is termed autoregulation. Resting coronary 
blood flow under normal hemodynamic conditions averages 0.7 – 1.0 ml / min / gm and can 
increase  between  four  and  five  fold  during  vasodilation4.  Circumstances  can  develop  that 
precipitate subendocardial ischemia in the presence of normal coronary arteries1.
Coronary flow can be auto regulated to mean coronary pressures as low as 40 mm Hg 
(diastolic pressures of 30 mmHg3 in humans without ischaemia).
Sub endocardial flow primarily occurs in diastole and begins to decrease below a mean 
coronary pressure of 40 mmHg3. In contrast, sub epicardial flow occurs throughout the cardiac 
cycle  and  is  maintained  until  coronary  pressure  falls  below 25  mmHg.  This  difference  is 
primarily related to the increased oxygen consumption in the sub endocardium.
ENDOTHELIUM – DEPENDENT MODULATION OF CORONARY TONE
Furchgott  and Zawadzki  originally  demonstrated that  acetyl  choline  normally dilates 
arteries via an endothelium – dependent relaxing factors that was later identified to be nitric 
oxide (NO)6. The major endothelium dependent biochemical pathways involved in regulating 
coronary epicardial and resistance artery diameter are as follows :
1. Nitric Oxide (Endothelium – Derived Relaxing Factor, EDRF)
NO is produced in endothelial cells. Endothelial NO diffuses abluminally into vascular 
smooth muscle where it binds to guanylate cyclase, increasing cGMP production and causing 
relaxation through a reduction in intracellular calcium. NO – mediated vasodilation is impaired 
in many disease states and in patients with one or more risk factors for coronary artery disease 
(CAD).
2. Prostacyclin
Metabolism of arachidonic acid via cycloxygenase can also produce prostacyclin, which 
is a coronary vasodilator when administered exogenously. There is evidence that prostacyclin 
contributes to tonic coronary vasodilation in humans.
In  contrast  to  the  native  resistance  vasculature,  vasodilator  prostaglandins  are  very 
important  determinants  of  coronary  collateral  vessel  tone  and  blocking  cyclo  oxygenase 
reduces collateral perfusion in dogs.
3. Endothelins
The endothelins (ET-1, ET-2, ET-3) are peptide endothelium – dependent constricting 
factors.  ET is  not involved in regulating coronary blood flow in the normal  heart  but  can 
modulate vascular tone when circulating concentrations increase in pathological states such as 
heart failure.
METABOLIC MEDIATORS OF CORONARY RESISTANCE
1. Adenosine
It  is  released  from cardiac  myocytes  and binds  to  A2 receptors  on  vascular  smooth 
muscle, increases cyclic adenosine monophosphate (cAMP), and opens intermediate calcium 
activated  potassium  channels8.  Adenosine  has  a  differential  effect  on  coronary  resistance 
arteries,  primarily  dilating  vessels  smaller  than  100µm7.  There  is  now substantial  in  vivo 
experimental data to demonstrate convincingly that it is not required for adjusting coronary 
flow to increases in metabolism (or) autoregulation9. It may, however contribute to vasodilation 
during hypoxia as well  as during acute exercise – induced myocardial ischemia distal  to a 
stenosis5.
2. K+ ATP Channels
Coronary vascular smooth muscle K+ - ATP channels are tonically active, contributing 
to coronary vascular tone under resting conditions by causing vasodilation.
3. Hypoxia
Although a potent coronary vasodilatory stimulus, the role of local PO2 in the regulation 
of arteriolar tone remains unresolved2.
4. Acidosis
Arterial  hypercapnea  and  acidosis  (PCO2)  are  potent  stimuli  that  have  been 
demonstrated to produce coronary vasodilation2 independent of hypoxia.
PARACRINE VASOACTIVE MEDIATORS AND CORONARY VASOSPASM
There are a large number of paracrine factors that can affect coronary tone in normal and 
pathophysiological states that are unrelated to normal coronary circulatory control.
1. SEROTONIN
Serotonin  released  from  activated  platelets  causes  vasoconstriction  in  normal  and 
atherosclerotic conduit arteries. Serotonin release generally exacerbates ischemia in CAD.
2. THROMBOXANE A2
Thromboxane  A2 is  a  potent  vasoconstrictor  and  can  accentuate  acute  myocardial 
ischemia.
3. ADENOSINE DIPHOSPHATE (ADP)
ADP is another platelet derived vasodilator that relaxes coronary microvessels as well as 
conduit arteries.
RISK FACTORS FOR ATHEROTHROMBOTIC DISEASE
Atherothrombosis can no longer be considered a disease of the developed world because 
by 2025, cardiovascular mortality on a world wide scale will likely surpass that of every major 
disease group including infection, cancer and trauma10,11.
CONVENTIONAL RISK FACTORS
Smoking 
Other than advanced age, smoking is the single most important risk factor for coronary 
artery disease. Cigarette consumption is the leading preventable cause of death in the united 
states, where it accounts for more than 4,50,000/- deaths annually12. 
Smokers have been found to have better outcome than non smokers after fibrinolysis in 
Acute MI in some studies74-78. This was attributed to a more complete reperfusion in smokers 
after thrombolysis.
In one study76, smokers were found to be of relatively younger age, normotensive, male 
gender and presented with inferior wall infarction more commonly. 
Hypertension
High  blood  pressure  often  confers  silent  cardio  vascular  risk  and  its  prevalence  is 
steadily increasing. In the framingham heart study, even high normal blood pressure (systolic 
BP   130  –  139  mmHg,  diastolic  BP   85  –  89  mmHg  or  both)  augments  risk  of 
cardiovascular disease two fold compared with lower levels13.
HYPERLIPIDEMIA  AND  ELEVATED  LOW–DENSITY  LIPOPROTEIN 
CHOLESTEROL
Substantiation of the relationship between total cholesterol and CHD risk emerged from 
the multiple risk factor intervention trial (MRFIT).
HIGH–DENSITY LIPOPROTEIN, CHOLESTEROL, APOLIPOPROTEIN AND 
OTHER LIPID SUB CLASSES
As  is  the  case  with  LDL  cholesterol,  abundant  prospective  cohort  studies  have 
demonstrated  a  strong  inverse  relationship  between  HDL cholesterol  and  vascular  risk.  In 
general, each increase of HDL cholesterol by 1 mg/dl is associated with a 2-3% decrease in risk 
of total cardio vascular disease. HDL could ferry cholesterol from the vessel wall, augmenting 
peripheral catabolism of cholesterol14.
TRIGLYCERIDE – RICH LIPOPROTEINS AND CARDIOVASCULAR RISK
The role of triglycerides remains controversial. Because triglyceride levels tend to vary 
inversely with HDL cholesterol levels, demonstration of an unequivocal effect of triglycerides 
on cardiovascular events and mortality independent of HDL levels has proved elusive.
METABOLIC SYNDROME, INSULIN RESISTANCE AND DIABETES
In one major survey, the presence of diabetes conferred an equivalent risk to aging 15 
years, an impact greater than that of smoking15.  Insulin resistance alone confers an elevated 
risk  of  congestive  heart  failure  and probably  explains  the  association  of  obesity  with  this 
common vascular complication16.
EXERCISE, WEIGHT LOSS AND OBESITY
Physical exercise reduces myocardial oxygen demand and increases exercise capacity, 
both of which correlate with lower levels of coronary risk.
Controversy remains as to whether obesity itself is a true risk factor for cardio vascular 
disease (or) whether its impact on vascular risk is mediated solely through inter relations with 
glucose intolerance, insulin resistance, hypertension, physical inactivity and dyslipidemia17.
hs – CRP
Levels of hsCRP greater than 3 mg / lit predict recurrent coronary events, thrombotic 
complications after angioplasty, poor outcome in the setting of unstable angina, and vascular 
complications after bypass surgery. Additionally, hsCRP has prognostic usefulness in cases of 
acute  ischemia,  even  without  troponin  level  elevation,  suggesting  that  an  enhanced 
inflammatory  response  at  the  time  of  hospital  admission  can  determine  subsequent  plaque 
rupture18.
OTHER MARKERS OF INFLAMMATION
These include cytokines such as interlukin – 6, soluble forms of certain cell adhesion 
molecules  such  as  intercellular  adhesion  molecule  (SICAM-1),   p-selectin  or  the  mediator 
CD40 ligand, as well as markers of leukocyte activation such as myeloperoxidase.
HOMOCYSTEINE
Patients  with  rare  inherited  defects  of  methionine  metabolism  can  develop  severe 
hyperhomocysteinemia (Plasma levels higher than 100 µmol/lit) and have markedly elevated 
risk of premature atherothrombosis as well as venous thromboembolism.
MARKERS OF FIBRINOLYTIC FUNCTION
Impaired  fibrinolysis  can  result  from  an  imbalance  between  the  clot  –  dissolving 
enzymes t  – PA (or) urokinase type plasminogen activator and their endogenous inhibitors, 
primarily PAI – 1. Plasma levels of PAI – I peak in the morning. On this basis, a relative 
hypofibrinolytic  state  may  prevail  in  the  morning.  That,  along  with  increased  platelet 
reactivity, may contribute to the increased risk of myocardial infarction seen during this period.
LIPOPROTEIN (a)
Lipoprotein (a) [LP(a)] consists of an LDL particle with its apolipoprotein B – 100 (apo 
B-100) component linked by a disulfide bridge to apolipoprotein (a) [apo(a)].
More  recent  studies  have  suggested  that  LP(a)  binds  and  inactivates  tissue  factor 
pathway inhibitor and may upregulate the expression of plasminogen activator inhibitor further 
linking lipoproteins and thrombosis.
GENETIC DETERMINANTS OF ATHEROTHROMBOSIS
Some  genetic  determinants  of  athero  thrombotic  cardiovascular  disease  are  well 
established and have been replicated in multiple cohorts. Carriers of the apoE e4 allele had a 
42% higher risk for coronary heart disease compared with those with the more common e3/3 
genotype, where as carriers of the e4 allele, had no significant increase in risk19. Other potential 
genetic determinants  of myocardial infarction reported in the cardio vascular literature include 
polymorphisms in the archidonate 5 – lipo oxygenase – activating protein gene and its related 
pathway,20,21 in the  cyclooxygenase – 2 gene,22 in the proprotein convertase subtilis in – kexin 
type 9 (pcsk9)23 gene, in the 0 x 40 ligand gene24 and in the ROS gene encoding for tyrosine 
kinase.
ST  –  ELEVATION  MYOCARDIAL  INFARCTION  PATHOLOGY, 
PATHOPHYSIOLOGY AND CLINICAL FEATURES
The pathological diagnosis of myocardial infarction requires evidence of myocyte cell 
death  as  a  consequence  of  prolonged ischemia.  Characteristic  findings  include  coagulation 
necrosis and contraction band necrosis, often with patchy area of myocytolysis at the periphery 
of the infarct.
The clinical diagnosis of MI requires an integrated assessment of the history with some 
combination  of  indirect  evidence  of  myocardial  necrosis  using  biochemical, 
electrocardiographic and imaging modalities.
Of  particular  concern  from an  global  perspective  are  projections  that  the  burden of 
disease  in  developing  countries  will  become  similar  to  those  now  afflicting  developed 
countries25.
The  short  term  mortality  rate  of  patients  with  STEMI  who  receive  aggressive 
pharmacological  reperfusion therapy as part  of  a  randomized trial  is  in the range of 6.5 – 
7.5%28. Where as observational data bases suggest that the mortality rate in STEMI patients in 
community is 15 – 20%29. In part, this difference relates to the selection of patients without 
serious Comorbidities for clinical trials.
REVISED  DEFINITION  OF  MYOCARDIAL  INFARCTION  (MI),  CRITERIA FOR 
ACUTE, EVOLVING (OR) RECENT MI
Either of the following criteria satisfies the diagnosis for acute, evolving (or) recent MI.
1. Typical rise and / or fall of biochemical markers of myocardial necrosis with atleast 
one of the following :
a. Ischemic symptoms
b. Development of pathological `Q’ waves in ECG
c. ECG changes indicative of ischemia (ST segment elevation (or) depression).
d. Imaging evidence of new loss of viable myocardium (or) new regional wall 
motion abnormality.
2. Pathological findings of an acute MI.
PATHOLOGY
Almost  all  MIs  result  from  coronary  atherosclerosis,  generally  with  superimposed 
coronary thrombosis. Non – atherogenic forms of coronary artery disease are also there.
Contemporary  studies  using  cardiac  magnetic  resonance  imaging  indicate  that  the 
development of a Q-wave on the ECG is determined more by the size of the infarct than the 
depth of  mural  involvement30.  A more suitable  framework that  puts  STEMI in perspective 
along with unstable angina / non – ST elevation MI (UA / NSTEMI) based on pathophysiology 
is referred to as the acute coronary syndromes (ACS).
PLAQUE
During the  natural  evolution of  atherosclerotic  plaque,  especially  that  which is  lipid 
laden,  an  abrupt  and  catastrophic  transition  can  occur,  characterized  by  plaque  disruption. 
Plaque  disruption  exposes  substances  that  promote  platelet  activation  and  aggregation, 
thrombin generation and ultimately thrombus formation31,32.
The composition of  the thrombus may vary at  different levels.  A white thrombus is 
composed of platelets, fibrin (or) both and a red thrombus is composed of erythrocytes, fibrin, 
platelets and leukocytes.
CAUSES  OF  MYOCARDIAL  INFARCTION  WITHOUT  CORONARY 
ATHEROSCLEROSIS
1. Arteritis
2. Trauma to coronary arteries
3. Coronary mural thickening with metabolic disease (or) intimal proliferative disease
4. Emboli to coronary arteries
5. Congenital coronary artery anomalies
6. Luminal narrowing by other mechanism 
7. Hematological (in situ thrombosis) such as polycythemia vera, 
Disseminated Intravascular Coagulation (DIC)
8. Miscellaneous such as cocaine abuse, myocardial contusion.
ACUTE CORONARY SYNDROMES
When plaque  disruption  occurs,  a  sufficient  quantity  of  thrombogenic  substances  is 
exposed and the coronary artery lumen may become obstructed by a combination of platelets 
aggregates, fibrin and RBC that may produce an extensive thrombus filling a large segment of 
the infarct – related artery.
Disruption of plaques is now considered to underlie  most acute coronary syndromes 
(ACS)27. Characteristically, such completely occlusive thrombi lead to a large zone of necrosis 
typically producing ST elevation on the ECG (STEMI – ST elevation myocardial infarction).
Patients presenting without ST elevation are initially diagnosed as suffering either from 
unstable angina (or) NSTEMI (Non ST Elevation MI).
Patients presenting with persistent ST segment elevation are candidates for reperfusion 
therapy (either pharmacological (or) catheter based) to restore flow in the occluded epicardial 
infarct related artery. ACS patients presenting without ST segment elevation are not candidates 
for pharmacological reperfusion but should receive anti ischemic therapy, followed by PCI. All 
patients with ACS should receive antithrombin therapy and antiplatelet therapy regardless of 
the presence (or) absence of ST – segment elevation.
Prognostic  considerations  must  take  into  account  other  important  factors,  such  as 
whether the ECG abnormality is caused by a first infarct versus subsequent infarct, the location 
of infarction (anterior versus inferior),  infarct  size and demographic factors  such as patient 
age26.
CLINICAL FEATURES
Predisposing Factors
Evidence suggests that unusually heavy exercise (particularly in fatigued (or) habitually 
inactive patients) and emotional stress can precipitate STEMI33. Such infarction could result 
from marked increases in myocardial oxygen consumption in the presence of severe coronary 
arterial narrowing35,37.
CIRCADIAN PERIODICITY
The time of onset of STEMI has a pronounced circadian periodicity, with peak incidence 
of events between 6 am and noon38. 
HISTORY
PRODROMAL SYMPTOMS
The prodrome is usually characterized by chest discomfort, resembling classic angina 
pectoris,  but it occurs at rest (or) with less activity than usual and can therefore be classified as 
unstable angina.
NATURE OF THE PAIN
The  pain  of  STEMI  varies  in  intensity,  in  most  patients,  it  is  severe  and  in  some 
instances  intolerable.  The  pain  is  prolonged,  usually  lasting  for  more  than  30  mins  and 
frequently  for  a  number  of  hours.  The  discomfort  is  described  as  constricting,  crushing, 
oppressing (or) compressing. The pain is usually retrosternal in location, spreading frequently 
to both sides of the anterior chest,  with predilection for the left  side.  In other patients,  the 
discomfort of STEMI radiates to the shoulders, upper extremities, neck,  jaw and interscapular 
region again usually favoring the left side. Both angina pectoris and the pain of STEMI are 
thought to arise from nerve endings in ischemia (or) injured, but not necrotic myocardium.
The  pain  often  disappears  suddenly  and completely  when blood  flow to  the  infarct 
territory is restored. In patients in whom reocclusion occurs after fibrinolysis, pain recurs if the 
initial reperfusion has left viable myocardium. The recognition that pain implies ischemia and 
not infarction heightens the importance of seeking ways to relieve the ischemia, for which the 
pain is a marker.
OTHER SYMPTOMS
Nausea and vomiting. Occasionally, a patient complains of diarrhea (or) violent urge to 
defecate  during  the  acute  phase  of  STEMI.  Other  symptoms  include  feelings  of  profound 
weakness, dizziness, palpitation, cold perspiration, and a sense of impending doom.
LABORATORY FINDINGS
Serum Markers of Cardiac Damage
Creatine Kinase
Serum CK activity exceeds the normal range within 4 – 8 hrs after the onset of STEMI 
and declines to normal with in 2 – 3 days34.
CREATINE KINASE ISOENZYMES
Although small quantities of CK – MB isoenzyme occur in tissues other than the heart, 
elevated levels of CK – MB may be considered, for practical purposes, to be the result of MI 
(except in the case of trauma (or) surgery on the organs containing the enzyme). It has been 
proposed that a ratio (relative index) of CK – MB mass to CK activity of about 2.5 is indicative 
of myocardial rather than a skeletal source of the CK – MB elevation.
MYOGLOBIN
The  peak  levels  of  serum  myoglobin  are  reached  considerably  earlier  
(1 – 4 hrs) than peak values of serum CK. But, it lacks cardiac specificity.
CARDIAC – SPECIFIC TROPONINS
These include troponin C which binds Ca2+, troponin I (TnI) which binds to actin and 
inhibits actin – myosin interactions, and troponin T (TnT) which binds to tropomyosin, there by 
attaching the troponin complex to the thin filament.
Quantitative assays developed for cTnT and cTnI have been approved by the food and 
Drug Administration for clinical use39. The troponins cTnT and cTnI  begin to rise with in 3 hrs 
after the onset of STEMI and declines to normal with in 7 – 10 days.
CUT – OFF VALUES
CK – MB usually increases ten – twenty folds above the upper limit of the reference 
range, cTnT and cTnI typically increases more than 20 times above the reference range.
RECOMMENDATIONS FOR MEASUREMENT OF SERUM MARKERS
Retrospective diagnosis (or) diagnosis of MI in the presence of skeletal muscle injury is 
more readily accomplished with cTnT or cTnI. With increasing familiarity of clinicians with 
assays for the cardiac – specific troponins, it is anticipated that they will superside assays for 
CK – MB not only for the diagnosis of MI but also for assessment of reperfusion, reinfarction, 
and estimation of infarct size40,34.
ST – ELEVATION MYOCARDIAL INFARCTION : MANAGEMENT
Treatment includes at the time of onset of STEMI (prehospital issues, initial recognition 
and  management  in  the  emergency  department,  reperfusion),  hospital  management 
(medications, arrhythmics, complications, preparation for discharge) and secondary prevention 
of STEMI.
PREHOSPITAL FIBRINOLYSIS
Several randomized trials have evaluated the potential benefits of prehospital versus in 
hospital  fibrinolysis.  There  was  a  generally  consistent  observation  of  benefit  from  earlier 
treatment and a meta – anlaysis of all  the available trials demonstrated a 17% reduction in 
mortality42. The CAPTIM trial reported a trend toward a lower rate of mortality among STEMI 
patients receiving pre hospital fibrinolysis as compared with primary PCI, especially if patients 
were treated with in 2 hrs of the onset of symptoms43,44. The greatest reductions in mortality is 
observed when reperfusion can be initiated with in 60 – 90 mins of the onset of symptoms41.
Therefore  prehospital  fibrinolysis  is  reasonable  in  settings  in  which  physicians   are 
present  in the ambulance to authorize prehospital fibrinolysis45-47.
GENERAL TRATMENT MEASURES
Apart  from  Reperfusion  Therapy,  the  following  Management  Protocol  should  be 
followed. 
Sample Admitting Orders for the STEMI patient : 
1. Condition : serious
2. IV : NS (or) D5W to keep vein open. Start a second IV if IV medication is being 
given.
3. Vital signs : monitor HR, BP and respiratory rate.
4. Monitor : continuous ECG monitoring for dysrhythmia and ST segment deviation.
5. Diet : NPO except for sips of water until stable.
6. Activity : Bedside commode and light activity when stable.
7. Oxygen : Continuous oximetry monitoring. Nasal cannula at 2 liters / min.
8. Medications :
a. Nitroglycerin (NTG)
b. Aspirin : (ASA, acetyl salicyclic acid)
c. Beta - Blocker
d. Angiotensin  converting enzyme (ACE) inhibitor
e. Angiotensin receptor blocker (ARB)
1. Start ARB orally in patients who are intolerant of ACE inhibitors.
f. Pain Medications
1. IV morphine sulfate 2 -4 mg with increments of 2 – 8 mg IV at 5 – 15 min 
intervals as needed to control pain.
g. Anxiolytics : based on a nursing assessment.
h. Daily stool softener.
ASSESSMENT OF REPERFUSION OPTIONS FOR STEMI PATIENTS
Step 1 : Assess time and risk
Step 2 : Determine if fibrinolysis (or) invasive strategy is preferred.
• If presentation is < 3 hrs and there is no delay to an invasive strategy, there 
is no preference for either strategy.
• Fibrinolysis is generally preferred if :
o Early presentation (< 3 hr from symptom onset and delay to invasive 
strategy)
An invasive strategy is generally preferred if :
* Skilled PCI lab is available with surgical back up
Skilled PCI lab is available, defined by 
- Medical contact to balloon (or) door to balloon less than 90 mins.
- (Door  to balloon) – (door  to needle) less than  1 hr.
* High risk from STEMI
- Cardiogenic shock
- Killip Class > 3
* Contraindications to fibrinolysis including increased risk of bleeding and ICH.
* Late presentation 
- Symptom onset was more than 3 hr ago.
* Diagnosis of STEMI is in doubt.
(ICH = Intra Cranial  Hemorrhage
 PCI = Percutaneous coronary intervention
STEMI= ST – Elevation myocardial infarction)
CONTRAINDICATIONS AND CAUTIONS FOR FIBRINOLYTIC USE IN STEMI
Absolute Contraindications
- Any prior intra cranial hemorrhage.
- Known structural cerebral vascular lesion (eg : arterio venous malformations)
- Known malignant intra cranial neoplasm (primary (or) metastatic)
- Ischemic stroke with in 3 months except acute ischemic stroke with in 3 hr.
- Suspected aortic dissection.
- Active bleeding  (or) bleeding diathesis (excluding menses).
- Significant closed head (or) facial trauma with in 3 months.
Relative Contraindications
* History of chronic severe poorly controlled hypertension.
* Severe uncontrolled hypertension on presentation (SBP > 180 mmHg (or) DBP > 
110 mmHg)
* History of prior ischemic stroke > 3 months, dementia (or) known intra cranial 
pathology not covered in contraindications.
* Traumatic (or) prolonged (> 10 min) CPR (or) major surgery (<3wk)
* Recent (with in 2 – 4 wk) internal bleeding
* Non compressible vascular punctures
* For streptokinase / anistreplase : prior exposure (>5 days ago) (or) prior allergic 
reaction to these agents.
* Pregnancy
* Active peptic ulcer 
EFFECTS OF MYOCARDIAL REPERFUSION
Rupture of an unstable plaque in the culprit vessel produces complete occlusion of the 
infarct related coronary artery. STEMI occurs with the ensuing development of left ventricular 
dilatation and ultimate death through a combination of pump failure and electrical instability. 
Early reperfusion shortens the duration of coronary occlusion, minimize the degree of ultimate 
left ventricular dysfunction.
INTRAVENOUS FIBRINOLYSIS
Timi Flow Grade
To provide a  level  of  standardization  for  comparison of  the  various  regimens,  most 
investigators describe the flow in the infarct vessel according to the thrombolysis in myocardial 
infarction (TIMI) trial grading system.
Gibson and Co-workers53 developed the  TIMI  frame count  –  a  simple  count  of  the 
number of angiographic frames elapsed until the contrast material arrives in the distal bed of 
the vessel of interest.
Grade 0 : complete occlusion of the infarct related artery, 
Grade 1 : some penetration of the contrast material beyond the point of obstruction but 
without perfusion of the distal coronary bed.
Grade 2 : perfusion of the entire infarct vessel into the distal bed but with delayed flow 
compared with a normal artery, 
Grade 3 : full perfusion of the infarct vessel with normal flow49,50.
The  majority  of  angiographic  studies  of  reperfusion  regimens  for  STEMI  used  an 
assessment of the TIMI flow grade at 90 (or) preferably 60 minutes after the start of fibrinolytic 
therapy51. TIMI grade 3 flow is far superior to grade 2 in terms of infarct size reduction and 
both short  term and long term mortality  benefit52.  Therefore  TIMI grade 3 flow should be 
considered to be the goal when assessing flow in the epicardial infarct artery52.
A convenient, simple, bedside risk scoring system for predicting 30  day mortality at 
presentation  for  fibrinolytic  eligible  patients  with  STEMI  was  developed  by  Marrow  and 
associates using the time  II trial data base57,58.
THE TIMI RISK  SCORE FOR ST ELEVATION MYOCARDIAL INFARCTION : A 
CONVENIENT,  BEDSIDE,  CLINICAL  SCORE  FOR  RISK  ASSESSMENT  AT 
PRESENTATION
1. Age 65 – 74 / > 75 yrs. - 2/3 points
2. Systolic blood pressure < 100 mm Hg - 3 points
3. Heart rate > 100 bpm - 2 points
4. Killip II – IV - 2 points
5. Anterior STE (or) LBBB - 1 point
6. Diabetes, h/o HTN (or)
h/o Angina - 1 point
7. Weight < 67 kg - 1 point
8. Time of treatment >4 hr - 1 point
Risk score - 0–14 possible points
(h/o  =  history of
HTN  =  hypertension
LBBB =  left bundle branch block
STE  =  ST segment elevation
TIMI  = Thrombosis in myocardial infarction)
COMPARISON OF APPROVED FIBRINOLYTIC AGENTS
Dose
Streptokinase Alteplase Reteplase TNK – tpA
1.5 mu in 30 – 
60 min
Upto 100 
mg in 90 
min (based 
on weight)
10U x 2 (30 
min apart) 
each over 2 
min
30 – 50 mg 
based on 
weight
Bolus 
administration
No No Yes Yes
Antigenic Yes No No No
Allergic reactions 
(hypotension 
most common)
Yes No No No
Systemic 
fibrinogen 
depletion
Marked Mild Moderate Minimal
90 – min patency 
rates (%)
~ 50 ~ 75 ~ 75 ~ 75
TIMI grade 3 
flow (%)
32 54 60 63
Cost per dose 
(U.S. $)
568 2750 2750
2750 for 50 
mg
(TNK  =   Tenecteplase, TIMI = Thrombolysis in Myocardial infarction)
COMPLICATION OF FIBRINOLYTIC THERAPY
Recent (< 1 yr) exposure to streptococci (or) streptokinase produces some degree of 
antibody – mediated resistance to streptokinase (and anistreplase) in most patients. Bleeding 
complications are, of course, most common and potentially the most serious. Most bleeding is 
relatively minor with all agents.  Intra cranial hemorrhage is the most serious complications of 
fibrinolytic therapy.
There have been reports of, an excess of deaths in the first 24 hrs in fibrinolytic treated 
patients compared with control subjects (especially in elderly patients treated more than 12 
hrs)48.  However, this excess early mortality is more than offset by the deaths prevented beyond 
the first day, culminating in an 18% (range 13 – 23%) reductions in mortality by 35 days48. The 
mechanisms responsible for this early hazard are not clear but are probably multiple, including 
an  increased  risk  of  myocardial  rupture  (particularly  in  the  elderly),  fatal  intra  cranial 
hemorrhage59,   inadequate myocardial reperfusion resulting in pump failure and cardiogenic 
shock60 and possible reperfusion injury of reperfused myocardium.
COMPLICATIONS OF MI
HEMODYNAMIC ASSESSMENT :
Hemodynamic Classification of patients with acute myocardial infarction
A. Based on Clinical 
Examination 
B. Based on Invasive 
Monitoring
Class Definition Subset Definition
I Rales and S3 absent I Normal hemodynamic 
PCWP < 18, CI > 2.2
II Crackles, S3 gallop, 
elevated jugular 
venous pressure
II Pulmonary congestion 
PCWP > 18, CI > 2.2
III Frank pulmonary 
edema
III Peripheral hypoperfusion 
PCWP < 18 CI < 2.2
IV Shock IV Pulmonary congestion 
and peripheral 
hypoperfusion PCWP > 
18, CI < 2.2
(A, Modified from Killip T, Kimball J.
B, From Forrester J, Diamond G, Chatterjee K, et al.,)
I. HEMODYNAMIC DISTURBANCES IN MI :
1. Left ventricular failure
2. Cardiogenic shock
3. Free wall rupture causing heart failure
4. Pseudo aneurysm causing heart failure
5. Rupture of the interventricular septum
6. Rupture of a papillary muscle
II. ARRHYTHMIAS :
1. Ventricular premature complexes
2. Ventricular tachycardia
3. Ventricular fibrillation
4. Sinus bradycardia
5. Atrio ventricular block
6. Intra ventricular block
7. Sinus tachycardia
8. Atrial flutter and fibrillation
III. OTHER COMPLICATIONS :
1. Pericardial effusion
2. Pericarditis
3. Dressler syndrome
4. Venous thrombosis and pulmonary embolism
5. Left ventricular aneurysm
6. Left ventricular thrombus and arterial embolism
CORONARY ARTERY BY PASS SURGERY
In  1964,  Garrett,  Dennis  and  DeBakey  first  used  CABG as  a  “bailout”  procedure. 
Widespread use of the technique by Favoloro and Johnson and their respective collaborators 
followed in the late 1960s. Use of the internal mammary artery (IMA) graft was pioneered by 
Kolessov in 1967 and by Green and colleagues in 1970.
INDICATIONS FOR CABG
1. Certain  anatomical  subsets  of  patients  are  candidates  for  CABG,  regardless  of  the 
severity of symptoms. Such patients include those with:
a. Significant left Main CAD;
b. Most patients with triple vessel disease that includes the proximal LAD coronary 
artery, especially those with LV dysfunction (ejection fraction less than 50%)
c. Patients  with  chronic  stable  angina  and  double  vessel  CAD  with  significant 
proximal disease of the LAD and either LV dysfunction (or) high risk findings on 
non invasive testing, should also be considered for CABG.
2. The  benefits  of  CABG  are  well  documented  in  patients  with  LV  dysfunction  and 
multivessel disease, regardless of symptoms.
3. Coronary  revascularization  with  PCI  or  CABG  is  highly  efficacious  in  relieving 
symptoms  and  may  be  considered  for  patients  with  moderate  to  severe  ischemic 
symptoms who are not controlled by and / or are dissatisfied with medical therapy even 
if  they  are  not  in  a  high  –  risk  subset.  For  such  patients,  the  optimal  method  of 
revascularization is selected on the basis of LV function and arteriographic findings and 
the likelihood of technical success.
COMPARISONS BETWEEN PCI AND CABG
Over a period of 1 – 5 years, the rates of mortality and non fatal infarction were not 
significantly different between patients revascularized with CABG versus PTCA, but recurrent 
events, including angina pectoris and the need for repeat revascularization procedures, were 
significantly more frequent in the PTCA than the CABG group largely as a consequence of 
incomplete revascularization and restenosis.  CABG was found to be associated with higher 
survival. These reveal the advantages of CABG.
The disadvantages of CABG are cost and morbidity. 
OTHER SURGICAL PROCEDURES FOR ISCHEMIC HEART DISEASE
Transmyocardial laser revascularization (TMLR) is performed by placing a laser on the 
epicardial  surface of the left  ventricle.  TMLR has been  reported to improve symptoms in 
patients with refractory angina.
MATERIALS AND METHODS
PLACE OF STUDY
This study was conducted in coronary care unit of GRH.
PERIOD OF STUDY
From January 2009 – September 2009
DESIGN
Observational prospective cohort study of patients receiving SK for acute myocardial 
infarction. A total of 75 patients were included in the study.
METHODOLOGY
SUBJECT SELECTION
1. Inclusion Criteria :
a. Presence of typical chest pain suggestive of acute myocardial infarction along with 
ECG evidence of AMI who were thrombolysed.
- Criteria for thrombolysis being 2 mm (or) more ST elevation in 2 contiguous 
precordial leads (or) 1 mm (or) more ST elevation in 2 contiguous limb leads. 
ECGs were recorded using Hewlett Packard page writer 100 machine.
b. TW of < 12 hrs from onset of pain to the initiation of thrombolysis.
2. Exclusion Criteria
a. Late thrombolysis (> 12 hrs from onset of pain)
b. Recurrent MI
c. Presence of left bundle branch block
d. Development of pericarditis
e. Smokers 
DRUG THERAPY
- All patients received SK 1.5 million units  in 100 ml NS over 60 minutes.
- Aspirin was given to all patients.
- Use of heparin, β-blockers, ACE inhibitors was according to CCU protocols, which 
was in accordance with ACC / AHA recommendation.
DEFINITION OF SUCCESS OF THROMBOLYSIS
Success was defined by 
1. Clinical – complete subsidence of chest pain.
2. Electrocardiographically – more than 50% ST resolution in a lead which showed 
maximum ST elevation initially. ST elevation is measured manually, 80 ms after J 
point from isoelectric line. Preceeding PR segment is taken as isoelectric line.
Patients were analysed for success of thrombolytic therapy at 90 mins, after initiation of 
thrombolytic therapy applying the above mentioned criteria. Those who underwent successful 
thrombolysis were grouped into a separate category and those who failed thrombolysis were 
grouped separately.
The following parameters were analysed among them to know whether they influenced 
the outcome of thrombolysis.
1. Age
2. Sex
3. Systemic hypertension
4. Diabetes mellitus
5. Location of myocardial infarction
6. Time interval between onset of pain and initiation of thrombolytic therapy.
DEFINITION
DIABETES MELLITUS
Patients were considered to be diabetic when :
1) currently on oral drugs and / or insulin therapy for DM 
(or)
2) hyperglycemia  detected  for  the  first  time  at  the  time  of  admission  and  required 
treatment for it even after discharge.
HYPERTENSION
Patients were considered hypertensive when :
1) they were already on anti – HT medications 
(or)
2) medically documented Bp > 140/90 mmHg on 2 (or) more occasions after admission 
and requiring anti hypertensive medications after discharge.
LOCATION OF MI
Inferior Wall infarction
• Patients with ST elevation with (or) without `q’ in L II, III,  avf were considered to 
have inferior wall MI.
• If the similar changes were seen in V5, V6, LI, AVL,  they were considered to have 
associated lateral wall MI.
• If they had ST elevation in V4R - V6R (Predominantly V4R), they were considered to 
have associated RVMI.
• If they had similar changes in V7 – V9 associated with mirror image changes in the 
form of ST depression and a wide R wave (> 40 milli secs.) in V1, V2, they were 
considered to have an associated posterior wall MI.
Extensive Anterior Wall  Infarction
Patients with ST elevation with (or) without `q’ in V1 – V6, LI, avL were considered to 
have extensive AWMI.
ASMI
Patients with ST elevation with (or) without `q’ in V1 – V4 were considered to have 
ASMI.
FOLLOW UP
- Patients were followed up until they were discharged from the hospital.
- ECHO was done whenever possible.
- Angiogram was not done due to unavailability.
STATISTICAL METHOD
Bivariate analysis  was done by chi-  square test  and multivariate analysis  by logistic 
regression method.
OBSERVATION AND ANALYSIS
A total of 75 patients were studied and their  age ranged from 28 – 72 years (mean 
55.26).  62  of  them were  males  (82.7%)  and  13  were  females  (17.3%).  18  of  them were 
hypertensive (24%) and 16 were  diabetic (21.3%). 24 patients  (32%) had extensive anterior 
wall  infarction,  22 patients  (29.3%)  had ASMI and 29 patients  (38.7%) had inferior  wall 
myocardial infarction. 28 patients (37.3%) were thrombolysed within 0 – 3 hrs from the onset 
of chest pain, 35 patients (46.7%) were thrombolysed within 3 – 6 hrs from the onset of chest 
pain and 12 patients (16%) were thrombolysed within 6 – 12 hrs from the onset of chest pain.
Among the  patients  observed in  this  study,  one  patient  had  died.  He  had extensive 
AWMI and had failed thrombolysis.
AGE DISTRIBUTION AMONG THE STUDY POPULATION
AGE
N Minimum Maximum Mean Std. Deviation
Age 75 28.00 72.00 55.2667 11.76726
Valid N (listwise) 75
AGE GROUP
Age Group Frequency Percent Valid Percent
Cumulative 
Percent
< or = 60 yrs 44 58.7 58.7 58.7
> 60 yrs 31 41.3 41.3 100.0
Total 75 100.0 100.0
SEX DISTRIBUTION AMONG THE STUDY POPULATION
Sex Frequency Percent
Valid 
Percent
Cumulative 
Percent
Female 13 17.3 17.3 17.3
Male 62 82.7 82.7 100.0
Total 75 100.0 100.0
DISTRIBUTION OF DIABETICS AMONG THE STUDY POPULATION
Diabetes Mellitus Frequency Percent
Valid 
Percent
Cumulative 
Percent
Absent 59 78.7 78.7 78.7
Present 16 21.3 21.3 100.0
Total 75 100.0 100.00
DISTRIBUTION OF HYPERTENSIVES AMONG THE STUDY 
POPULATION
Systemic 
Hypertension
Frequency Percent
Valid 
Percent
Cumulative 
Percent
Absent 57 76.0 76.0 76.0
Present 18 24.0 24.0 100.0
Total 75 100.0 100.0
DISTRIBUTION OF PATIENTS IN DIFFERENT TIME WINDOWS 
AMONG THE STUDY POPULATION
Time Window Frequency Percent
Valid 
Percent
Cumulative 
Percent
0 – 3 hrs 28 37.3 37.3 37.3
3 – 6 hrs 35 46.7 46.7 84.0
6 – 12 hrs 12 16.0 16.0 100.00
Total 75 100.0 100.0
DISTRIBUTION OF PATIENTS WITH DIFFERENT LOCATIONS OF MI 
AMONG THE STUDY POPULATION
Location of MI Frequency Percent
Valid 
Percent
Cumulative 
Percent
ASMI 22 29.3 29.3 29.3
Ext. Ant 24 32.0 32.0 61.3
Inf. Wall 29 38.7 38.7 100.00
Total 75 100.0 100.0
OUTCOME OF THROMBOLYSIS AMONG THE STUDY POPULATION
Outcome Frequency Percent
Valid 
Percent
Cumulative 
Percent
Success 40 53.3 53.3 53.3
Failure 35 46.0 46.7 100
Total 75 100.0 100.00 100
Bivariate Analysis – Study of factors influencing the outcome of thrombolysis in acute 
myocardial infarction patients
Chi-square test of independence: Comparison of the outcome of thrombolysis between the 
two age groups
Among  the  patients  with  age  <  60  years,  28  patients  (63.6%)  had  successful 
thrombolysis, while 12 patients (38.7%) were successful among those with age > 60 yrs. Age 
was a significant factor influencing the outcome of thrombolysis in bivariate analysis, but it 
turned out to be insignificant in multivariate anlaysis. 
Chi-Square Tests
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Chi-square test of independence: Comparison of the outcome of thrombolysis between 
males and females
Among the males 33 patients (53.2%) had successful thrombolysis, while among the 
females 7 patients (53.8%) had successful thrombolysis. The difference was insignificant.
Sex * Outcome Crosstabulation
7 6 13
53.8% 46.2% 100.0%
17.5% 17.1% 17.3%
33 29 62
53.2% 46.8% 100.0%
82.5% 82.9% 82.7%
40 35 75
53.3% 46.7% 100.0%
100.0% 100.0% 100.0%
Count
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Chi-square test of independence: Comparison of the outcome of thrombolysis between 
diabetics and non-diabetics.
Among  the  diabetics  9  patients  (56.3%)  had  successful  thrombolysis,  while  among 
nondiabetics  31  patients  (52.5%)  had  successful  thrombolysis.  The  difference  in  outcome 
between diabetics and non diabetics was insignificant.
Diabetes Mellitus * Outcome Crosstabulation
31 28 59
52.5% 47.5% 100.0%
77.5% 80.0% 78.7%
9 7 16
56.3% 43.8% 100.0%
22.5% 20.0% 21.3%
40 35 75
53.3% 46.7% 100.0%
100.0% 100.0% 100.0%
Count
% within Diabetes
Mellitus
% within Outcome
Count
% within Diabetes
Mellitus
% within Outcome
Count
% within Diabetes
Mellitus
% within Outcome
Absent
Present
Diabetes
Mellitus
Total
Success Failure
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Chi-square test of independence: Comparison of the outcome of thrombolysis between 
those with and without hypertension
Among the hypertensives 10 patients (55.6%) had successful outcome while among non 
hypertensive  30  patients  (52.6%)  had  successful  outcome.  The  difference  in  the  outcome 
between the two groups was insignificant.
Systemic Hypertension * Outcome Crosstabulation
30 27 57
52.6% 47.4% 100.0%
75.0% 77.1% 76.0%
10 8 18
55.6% 44.4% 100.0%
25.0% 22.9% 24.0%
40 35 75
53.3% 46.7% 100.0%
100.0% 100.0% 100.0%
Count
% within Systemic
Hypertension
% within Outcome
Count
% within Systemic
Hypertension
% within Outcome
Count
% within Systemic
Hypertension
% within Outcome
Absent
Present
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Success Failure
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Chi-square test of independence: Comparison of the outcome of thrombolysis between 
patients presenting in different time windows.
The number of patients who had successful outcome after thrombolysis were 18 (64.3%) 
among those in the time window of 0 – 3 hrs, 19 (54.3%) among those in the TW of 3 – 6 hrs 
and 3 (25%) among those in the TW of 6 – 12 hrs. Patients in 0 – 3 hrs had a higher success 
rate compared to those in 3 – 6 and 6 – 12 hrs group. The difference between 0 – 3 and 6 – 12 
hrs was statistically significant,  but the difference between 0 – 3 and 3 – 6 hrs group was 
statistically insignificant.
Time Window * Outcome Crosstabulation
18 10 28
64.3% 35.7% 100.0%
45.0% 28.6% 37.3%
19 16 35
54.3% 45.7% 100.0%
47.5% 45.7% 46.7%
3 9 12
25.0% 75.0% 100.0%
7.5% 25.7% 16.0%
40 35 75
53.3% 46.7% 100.0%
100.0% 100.0% 100.0%
Count
% within Time Window
% within Outcome
Count
% within Time Window
% within Outcome
Count
% within Time Window
% within Outcome
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Chi-square test of independence: Comparison of the outcome of thrombolysis between 
patients presenting with MI at different sites.
The number of patients who had successful outcome after thrombolysis was 7 (31.8%) 
among those with ASMI, 11 (45.8%) among those with extensive anterior wall MI and 22 
(75.9%) among those with inferior wall MI. Patients with inferior wall MI had higher success 
rate which was statistically significant.
Location of MI * Outcome Crosstabulation
7 15 22
31.8% 68.2% 100.0%
17.5% 42.9% 29.3%
11 13 24
45.8% 54.2% 100.0%
27.5% 37.1% 32.0%
22 7 29
75.9% 24.1% 100.0%
55.0% 20.0% 38.7%
40 35 75
53.3% 46.7% 100.0%
100.0% 100.0% 100.0%
Count
% within Location of MI
% within Outcome
Count
% within Location of MI
% within Outcome
Count
% within Location of MI
% within Outcome
Count
% within Location of MI
% within Outcome
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Success Failure
Outcome
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DISCUSSION
INFLUENCE OF AGE OF THE PATIENT ON OUTCOME OF THROMBOLYSIS 
Patients > 60 yrs were found to have lesser success rate in bivariate analysis (p = 0.033). 
After  adjustment  for  other  parameter  in  logistic  regression,  a  statistically  insignificant 
difference in success rate is observed but odds ratio 0.947 for age indicates that a year increase 
in  age  decreases  the  odds  in  favour  of  success  by  6%.  This  shows  that  with  respect  to 
fibrinolysis elderly people do not behave differently from younger people. This is reflected in 
decrease of mortality rate among elderly after thrombolysis. In patients aged > 75 years who 
were treated with SK in GISSI - 2 trials, there were 4.2 fewer deaths per 100 patients than in 
controls. In ISIS – 2 there was 3.3 fewer deaths per 100 patients in those over 70 yrs of age 
who  were  treated.  The  mortality  effect  of  fibrinolytic  therapy  in  elderly  patients  is  of 
considerable interest and controversy. 
Barriers to initation of therapy in older patients with STEMI include a protracted period 
of  delay  in  seeking  medical  care,  a  lower  incidence  of  ischemic  discomfort  and  greater 
incidence of atypical symptoms and concomitant illness and an increased incidence of non – 
diagnostic ECG readings41. Younger patients with STEMI achieve a slightly greater relative 
reduction in mortality compared with elderly patients, but the higher absolute mortality in the 
elderly results in similar absolute mortality reductions. 
Results of FTT group which performed a comprehensive  over view of nine trials of 
thrombolytic treatment, each of which enrolled more than 1000 patients showed, there was a 
26% decrease in mortality in patients who were younger than 55 years of age and 4% reduction 
in mortality in patients older than 75 years of age56.
Other studies done to assess the effect of Age on the outcome of thrombolytic therapy 
and mortality in Acute MI have shown more beneficial effects in patients less than 55 years64,65.
GENDER
No statistically significant difference was noticed based on gender.
Lunderberg – CF, Topoi et al., performed an angiographic study to find out the patency 
rate at 90 mins in men versus women. At 90 min TIMI – 3 flow rate was 39% in women and 
38% in men, which was not statistically significant.
But 30 day mortality was 13.1% in women versus 8% in men (p=0.001).
Thus even though females have a poor outcome after MI, they donot behave differently 
to thrombolytic treatment.
Some of the studies done to assess the effect of Gender on the outcome of thrombolytic 
therapy and mortality  in Acute MI have shown insignificant differences between male and 
female sexes66-68.
DIABETES MELLITUS
In this study, success rate of thrombolysis was not found to be different in diabetics 
from non – diabetic population.
Gray  RP,  Yudkin  J.  et  al.,  found  a  reduction  in  reperfusion  rates  in  thrombolysed 
diabetic patients.
Diabetes is a prothrombotic state as reflected by the increased bloodlevels of fibrinogen, 
factor VII,  vwf.  These changes are even more increased if diabetic  people happened to be 
smokers.
Platelet function is also impaired in diabetes. They aggregate more readily to stimuli like 
ADP and collagen.  Glycation of  membrane protein due to chronic  exposure to  high blood 
glucose levels, change in fluidity of platelet membrane brought about by high concentration of 
cholesterol and triglycerides are proposed mechanisms for these abnormalities.
On the other hand patients with T2 DM have profound suppression of fibrinolysis. PA 
inhibitor I (plasminogen activator) levels are increased in T2DM, which is responsible for this 
effect.
Nevertheless thrombolytic therapy should be administered to diabetes with acute MI, 
because for every 100 patients treated with thrombolytic drugs, four lives are saved.
Results  of  FTT group which  performed a  comprehensive  overview of  nine  trials  of 
thrombolytic treatment each of which enrolled more than 1000 patients showed that patients 
with a history of diabetes mellitus experienced a mortality reduction of 21% compared with a 
mortality reductions of 15% in patients without diabetes.
Some of the studies done to assess the effect of diabetes on the outcome of thrombolytic 
therapy  and  mortality  in  Acute  MI  did  not  show any  difference  in  the  outcome  between 
diabetics and non-diabetics69-71.  
HYPERTENSION
In this study, success rate of thrombolysis is not found to be different in hypertensives 
from non hypertensives.
Results  of  FTT group which performed a  comprehensive  overview of  nine  trials  of 
thrombolytic treatment each of which enrolled more than 1000 patients showed that there was 
an 18% decrease in mortality for patients presenting with a systolic pressure less than 100 
mmHg, compared with a 12% reduction in mortality for patients with an systolic pressure of 
175 mmHg (or) more.
Some  of  the  studies  done  to  assess  the  effect  of  hypertension  on  the  outcome  of 
thrombolytic  therapy  and  mortality  in  acute  MI  have  shown  better  outcome  in  non 
hypertensives than hypertensives72,73.
SITE OF INFARCTION
The major finding  of this study is that location of the infarct affects the outcome of 
thrombolysis.  Those  with  inferior  wall  MI  are  4  times  more  likely  to  undergo  successful 
thrombolysis  compared  to  ASMI.  (Odds  ratio  0.232).  This  is  after  adjustment  for  all 
confounding variables like time window, age, gender, diabetes and hypertension.
Similar observation were made by Michael Gibson, Sabina, Murphy and E.Brawnwald 
et  al.,  TIMI  study  group.  They  found  that  TIMI  grade  III  flow rates  were  lower  for  left 
coronary and circumflex artery, compared to RCA after thrombolytic treatment.
The reason for this different response will be evident when we look at the physiology of 
coronary circulation in right and left coronary artery.
Blood flow in RCA is independent of phases of cardiac cycle, being present in the both 
systole and diastole, whereas flow in left coronary artery is almost absent during systole and 
may even be reversed in conditions of heightened microvascular tone and LVH.
The relative thicker wall, the increased wall thickening during systolic contraction and 
higher intra cavitary pressure of LV may all produce higher intra myocardial pressure than that 
is  observed  in  the  thinner  walled  right  ventricle  which  is  also  subjected  to  lower  filling 
pressure.
More  over  the  extent  of  necrosis  in  anterior  wall  is  more  resulting  in  increased 
myocardial wall edema, compared to inferior wall infarction. This may further decrease the 
reperfusion  rates  in  anterior  wall  infarction.  Yet  another  mechanism  may  be  better  drug 
delivery to the RCA and prolonged contact of SK with the thrombus resulting in more efficient 
fibrinolysis.
TIME WINDOW (TW)
This is the most powerful predictor of success rate which was evident in this study also. 
The success rate of patients thrombolysed within 3 hrs from onset of symptom was 64.3%. The 
success rate of patients thrombolysed between 3 and 6 hrs after the onset of symptoms was 
54.3%. The success rate of patients thrombolysed  between 6 and 12 hrs from the onset of 
symptoms was 25%.
There  is  significant  difference  (sign.  at  10%)  in  the  success  rate  between  those 
thrombolysed  in 0 – 3 hours time TW and 6 – 12 hours TW.
Odds ratio of 3.35 indicates that patients in 0 – 3 hours TW group were 3.35 times more 
likely to have success when compared to patients in 6 – 12 hours TW group.
Early intravenous fibrinolysis undoubtedly improves survival in patients with STEMI41. 
Mortality varies considerably depending on the patients included for study and the adjunctive 
therapies employed. The benefit of fibrinolytic therapy appears to be greatest when agents are 
administered as early as possible with the most dramatic results when the drug is given less 
than 2 hours after symptoms beign55.
The data from LATE, EMERAS and the FTT over view form the basis for extending the 
window of treatment with fibrinolysis upto 12 hrs from the onset of symptoms. Boersma and 
colleagues pooled the trials in the FTT overview, the two smaller studies with data on time to 
randomization and the 11 additional trials of more than 100 patients55. Patients were divided 
into six time categories from symptom onset to randomization. A non – linear relationship of 
treatment benefit to time was observed, with the greatest benefit occurring in the first 1 to 2 hrs 
from the onset of sysmptoms55.
The impact of time to thrombolytic  treatment on outcome in patients with acute MI 
study by Gibbons and Roberts have shown better outcome with early thrombolysis74.
CIRCADIAN VARIATION
Eugene  Brawnwald  et  al.,  noticed  a  circadian  variation  in  efficacy  of  thrombolytic 
treatment with better patency in the evening hours. This is due to circadian variation in the 
blood levels of PAI – I, which is lower in the evening hours.
In  this  study  no  such  circadian  variation  was  observed.  Probable  reasons  for  this 
discrepancy may be shorter time window observed in patients presenting in morning hours as 
well as smaller sample size.
SENSITIVITY AND SPECIFICITY
Sensitivity and specificity of the method used for multivariate analysis here were :
Sensitivity - 75%
Specificity - 68.6%
Mortality  differences during days 0 – 35 subdivided by presentation features in 
collaborative overview of results from nine trials of thrombolytic therapy. The absolute 
mortality rates are shown for patients who underwent fibrnolysis 
Presentation Features Mortality in Patients after fibrinolytic therapy
ECG 
BBB 18.7%
ST elev, Anterior 13.2%
ST elev, Inferior 7.5%
ST elev other 10.6%
ST depression 15.2%
Other abnormality 5.2%
Normal 3.0%
Hours from onset 
0 – 1 9.5%
2-3 8.2%
4-6 9.7%
7-12 11.1%
13-24 10.0%
Age (years)
< 55 3.4%
55 – 64 7.2%
65 – 74 13.5%
75+ 24.3%
Gender 
Male 8.2%
Female 14.1%
Systolic BP (mm Hg) 
< 100 28.9%
100 – 149 9.6%
150 – 174 7.2%
175+ 7.2%
Diabetes 
Yes 13.6%
No 8.7%
All Patients 9.6%
(BBB - bundle branch block, BP - Blood pressure) 
From Fibrinolytic Therapy Trialists (FTT) Collaborative Group: Collaborative over view of 
mortality and major morbidity results from all randomized trials of more than 1000 patients. 
Lancet 343:311, 1994.
SUMMARY
• In this study the overall success rate of thrombolysis among non smokers was 53.3%.
• There was trend towards favourable outcome in those < 60 years and worse outcome 
in those with age > 60 years. It was statistically insignificant.
• Gender was not found to influence the success rate of thrombolysis.
• Diabetics  do  not  differ  from non –  diabetics  with  respect  to  the  success  rate  of 
thrombolysis.
• Hypertensive patients did not show any difference from non hypertensive patients 
with respect to success rate of thrombolysis.
• Time window was a significant factor influencing the outcome in AMI. Patients who 
presented in the 0–3 hours time window and 3–6 hours time window had higher 
success rate when compared to patients who presented in time window of 6–12 hrs. 
Difference  in  outcome  after  thrombolysis  between  0–3  and  3–6  hrs  group  was 
statistically insignificant.
• Site  of  infarction  was  also  a  significant  factor.  Patients  with  Inferior  wall  MI  had 
significantly higher success rate when compared to   ASMI.
CONCLUSION
The study was conducted to evaluate the success rate of thrombolysis in acute MI and 
the various factors influencing its outcome among non smokers. It was done by observational 
prospective cohort study of patients receiving SK for acute MI in ICCU in GRH, Chennai. 
The overall success rate of thrombolysis among non smokers here was 53.3%. 
Patients with inferior wall MI had a significantly better outcome compared to patients 
with  ASMI.
Age influenced the outcome but was not statistically significant. 
Early thrombolysis had a better outcome when compared to other factors.
Success  rate  was  64.3% in  those  patients  thrombolysed  within  3  hrs  from onset  of 
symptoms. Time window was found to be the most powerful factor influencing the outcome of 
thrombolysis in patients with acute myocardial infarction.
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      ABBREVIATIONS
LAD - Left Anterior Descending Artery
LCA - Left coronary artery
LCX - Left circumflex artery
RCA - Right coronary artery
LV - Left ventricle
RV - Right ventricle
R tpA - Recombinant tissue plasminogen activator
CABG - Coronary artery bypass Graft
PAI – I - Plasminogen activator inhibitor - I
SK - Streptokinase
PDGF - Platelet Derived growth factor
VWF - Von willebrand factor
APSAC - Anisoylated plasminogen SK activator complex
LBBB - Left bundle branch block
RBBB - right bundle branch block
SCD - Sudden cardiac death
GRH - Government Royapettah Hospital
RVMI - Right ventricular myocardial infarction
MI - Myocardial infarction
AMI - Acute myocardial infarction
DM - Diabetes mellitus
SHT - Systemic hypertension
ICCU - Intensive coronary care unit
GISSI - Gruppo Italiano Per lo studio della 
Streptochinasi nell’ infarto miocardico. 
GUSTO - Global Utilization of Streptokinase and t–pA for  
Occluded coronary arteries.
ISIS - International Study of Infarct Survival. 
PROFORMA
Name : IP : 
Age  : Occupation :
Sex  : Monthly income :
Personal Data :
1. Smoking Yes No
If Yes – No. of Cigarettes / day
2. Drinking Yes No
If Yes – ml / week
3. Life Style 
4. Hypertension Yes No
If yes, 1) Duration
2) Treatment regular / irregular
Exercise regularly
> 3 times / week
Active
Sedentary
5. Diabetes Yes No
If Yes,
Duration - Insulin
Type I Type II Oral 
Durgs
6. Hyper lipidemia Yes No
Treatment with
a. Diet alone
b. Drugs
a. Hyper triglyceremia
b. Hyper cholesterolemia
c. Mixed
d. Other diseases – specify 
Family history of
SCD AMI Stroke
Time of onset of symptoms
0 – 6 AM 6 – 12 noon 12 – 6 pm 6 – 12 midnight
Physical Examination
Pulse -
Bp -
JVP -
S3 -
Crackles -
Murmur -
Rub -
Time of SK administration
0 – 6 AM 6 – 12 noon 12 – 6 pm 6 – 12 midnight
Pain onset to SK administration interval in hrs.
0 – 3 hrs 3 – 6 hrs 6 – 12 hrs
ECG on admission 
1. Location of MI
Ext. Ant AS AL Inf. IP IPL RVMI
2. Peak ST elevation in millimeter
ECG at 90 min after SK therapy :
Maximal ST elevation in mm 
Percentage ST resolution 
Clinical condition at 90 mins
• No angina
• Decreased pain
• Persistent with same intensity
Arrhythmias if any during thrombolysis -
Thrombolysis successful 
Other events and intervention if any 
Lab data :
Hb%, TC, DC, ESR
Sugar
Urea
Creatinine
Yes No
Na+, 
K+
Echo
Angiogram
Follow up
